TEVA(TEVA) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenues increased by 5% to $1.7 billion, EBITDA grew by 12% to $5.3 billion, EPS rose by 19% to $2.93, and free cash flow was up 16% to $2.4 billion [7][28] - Net debt to EBITDA ratio improved to 2.5x, with a target of 2x by 2027 [8][28] Business Line Data and Key Metrics Changes - Innovative portfolio showed strong growth: AUSTEDO grew by 34% to $2.26 billion, UZEDY increased by 63% to $191 million, and AJOVY rose by 30% to $673 million [9][10][14] - Generics business remained flat, with U.S. growth at 2%, international markets at 1%, and Europe declining by 2% [16][17] Market Data and Key Metrics Changes - The U.S. generics market faced challenges, particularly with the loss of generic Revlimid revenue, impacting overall growth [34] - The biosimilars portfolio is expected to grow by $400 million by 2027, with 10 assets currently in the market and six additional launches planned [18] Company Strategy and Development Direction - The company is focused on its "Pivot to Growth" strategy, emphasizing innovation and a shift from generics to biopharma [4][28] - A target of $700 million in net savings by 2027 is set, with $70 million achieved in 2025 [29][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-term financial targets for 2030, with a focus on innovative products driving growth [28][41] - The company anticipates a gradual revenue increase in 2026, despite challenges from generic Revlimid [34][39] Other Important Information - The company is on track to achieve a non-GAAP operating margin target of 30% by 2027 [29][33] - Significant milestones in the pipeline are expected in 2026, including data releases for Duvakitug and Olanzapine LAI [43][44] Q&A Session Summary Question: Insights on AUSTEDO and UZEDY pricing dynamics - Management highlighted strong TRx growth for AUSTEDO and maintained a disciplined approach to pricing, expecting continued growth despite competitive pressures [50][51] - For UZEDY, management acknowledged the mix of Medicaid and Medicare affecting profitability but remains optimistic about continued momentum [53] Question: Disconnect between pipeline excitement and market perception - Management noted that the rapid development of the pipeline may have surprised investors, emphasizing the quality and potential of new products [57][59] Question: Funding R&D and balancing partnerships - Management stated that partnerships do not significantly impact economics, as new product launches enhance gross margins and EBITDA [65][66] Question: Expectations for TL1A maintenance data - Management expressed optimism about the upcoming maintenance data, citing the product's potency and selectivity as key advantages [70]